Improvement of cardiac function with parecoxib, a cyclo-oxygenase-2 inhibitor, in a rat model of ischemic heart failure.

Abstract

OBJECTIVE:

To assess changes in cardiac function in animals with ischemic congestive heart failure (CHF) treated with a selective cyclo-oxygenase-2 (COX-2) inhibitor.

BACKGROUND:

In patients with CHF, COX-2 expression was associated with features of worsening failure. However, evidence of beneficial or detrimental functional effects of COX-2 inhibition in ischemic CHF is lacking.

METHODS:

Thirty male Wistar rats underwent coronary ligation and were allowed to recover for 12 months. Five sham-operated animals were used as controls. After 12 months, six surviving animals underwent baseline echocardiogram to measure end-diastolic diameter (EDD), end-systolic diameters (ESD), fractional shortening (FS), and anterior and posterior diastolic and systolic wall thicknesses. The animals were thereafter treated by daily intraperitoneal parecoxib injections (0.75 mg/kg) for 7 days. On day 7, a repeat echocardiogram was performed.

RESULTS:

When compared to baseline, repeat echocardiography after 7 days of parecoxib treatment showed no changes in the EDD (9.4 +/- 0.4 mm vs. 9.4 +/- 0.3 mm, P = 0.9), a significant reduction of ESD (5.5 +/- 0.8 mm vs. 6.4 +/- 0.3 mm, P = 0.028), and a significant improvement in the FS (43 +/- 3% vs. 32 +/- 5%, P = 0.027). Improvement of FS was associated with a significant change in systolic thickness in the infarct zone (3.6 +/- 0.4 mm vs. 3.0 +/- 0.1 mm, P = 0.046), whereas no significant changes in systolic thickness in the remote area were observed.

CONCLUSIONS:

Administration of parecoxib in ischemic CHF provides functional improvement of the peri-infarct myocardium. This finding may prove useful in improving quality of life and, perhaps, survival in patients with ischemic heart disease.

• Authors: Antonio Abbate, Fadi N Salloum, Ramzi A Ockaili, Alpha A Fowler 3rd, Giuseppe G L Biondi-Zoccai, Stefania Straino, Michael J Lipinski, Alfonso Baldi, Filippo Crea, Luigi M Biasucci, George W Vetrovec, Rakesh C Kukreja
• Journal: Journal of cardiovascular pharmacology (J Cardiovasc Pharmacol) Vol. 49 Issue 6 Pg. 416-8 (Jun 2007) ISSN: 0160-2446 [Print] United States
• PMID: 17577107 (Publication Type: Journal Article)

Chemical References

• Cyclooxygenase 2 Inhibitors
• Isoxazoles
• parecoxib
• Cyclooxygenase 2

Topics

• Animals
• Cyclooxygenase 2 (biosynthesis)
• Cyclooxygenase 2 Inhibitors (administration & dosage, pharmacology, therapeutic use)
• Disease Models, Animal
• Echocardiography
• Heart Failure (etiology, prevention & control)
• Heart Function Tests
• Isoxazoles (administration & dosage, pharmacology, therapeutic use)
• Male
• Myocardial Ischemia (complications)
• Myocardium (enzymology, pathology)
• Rats
• Rats, Wistar